We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Key Takeaways BioNTech's U.S.-listed shares surged more than 15% Monday morning after the company said it will partner with ...

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with ...

Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...